Drug Patents owned by Bristol Myers Squibb

1. Drug name - ELIQUIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(4 years from now)

CN101357914A BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
Apr, 2012

(10 years ago)

CN1578660A BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
Sep, 2022

(15 days ago)

CN1578660B BRISTOL MYERS SQUIBB Lactam Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
Sep, 2022

(15 days ago)

IN200400590P1 BRISTOL MYERS SQUIBB A Novel Compound Of Formula (1)
Sep, 2022

(15 days ago)

IN247381B BRISTOL MYERS SQUIBB A Novel Compound Of Formula (1)
Sep, 2022

(15 days ago)

EP2105436B1 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
Sep, 2022

(15 days ago)

EP2105436A1 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
Sep, 2022

(15 days ago)

EP1427415A1 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
May, 2026

(3 years from now)

EP1427415B1 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
May, 2026

(3 years from now)

EP1427415A4 BRISTOL MYERS SQUIBB Lactam-Containing Compounds And Derivatives Thereof As Factor Xa Inhibitors
May, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326945 BRISTOL MYERS SQUIBB Apixaban formulations Feb, 2031

(8 years from now)

Drugs and Companies using APIXABAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

2. Drug name - SPRYCEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(3 years from now)

CN1980909B BRISTOL MYERS SQUIBB As Kinase Inhibitor 2-Amino Thiazole -5 - Aromatic Methanamide Preparation Method
Feb, 2022

(7 months ago)

CN1980909A BRISTOL MYERS SQUIBB Preparation Method Of 2-Aminothiazole-5-Aromatic Methanamide Regarded As Kinase Inhibiter
Feb, 2022

(7 months ago)

EP1711481A2 BRISTOL MYERS SQUIBB Process For Preparing 2-Aminothiazole-5-Aromatic Carboxamides As Kinase Inhibitors
Feb, 2025

(2 years from now)

EP1711481B2 BRISTOL MYERS SQUIBB Crystalline Monohydrate As Kinase Inhibitors
Feb, 2025

(2 years from now)

EP1711481B1 BRISTOL MYERS SQUIBB Crystalline Monohydrate As Kinase Inhibitors
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Feb, 2025

(2 years from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Aug, 2025

(2 years from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors Sep, 2026

(3 years from now)

Drugs and Companies using DASATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
70MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
140MG TABLET;ORAL Prescription

3. Drug name - ZERIT XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7135465 BRISTOL MYERS SQUIBB Sustained release beadlets containing stavudine Feb, 2023

(4 months from now)

US7135465

(Pediatric)

BRISTOL MYERS SQUIBB Sustained release beadlets containing stavudine Aug, 2023

(10 months from now)

Drugs and Companies using STAVUDINE ingredient

Treatment: Method for treating hiv-1 infection

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
37.5MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
50MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
75MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
100MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.